Capecitabine and oxaliplatin are recommended as possible adjuvant treatments after surgery for stage III (Dukes’ C) colon cancer, when used in the following ways:

  • capecitabine on its own
  • oxaliplatin together with 5-fluorouracil and folinic acid.

The choice of treatment should be decided jointly by the individual and their doctors, after they have discussed the options. This discussion should cover any contraindications to the treatments (reasons why a particular medicine might not be suitable for the person), the possible side effects of the treatments, and the different ways they can be given. It should also take into account the person’s clinical condition and individual preferences.

Your responsibility

The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected to take this guidance fully into account, alongside the individual needs, preferences and values of their patients. The application of the recommendations in this guidance is at the discretion of health professionals and their individual patients and do not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.

Commissioners and/or providers have a responsibility to provide the funding required to enable the guidance to be applied when individual health professionals and their patients wish to use it, in accordance with the NHS Constitution. They should do so in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities.

Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible.